Rigel Pharmaceuticals, Inc.
RIGLHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Rigel Pharmaceuticals, Inc. (RIGL) is listed under Biotechnology. Valued at $909.1M, RIGL is a small-cap name in its sector. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Market Cap
$909.1M
Beta
1.20
P/E (TTM)
2.88
P/E (Fwd)
9.85
EPS (TTM)
$16.88
EPS (Fwd)
$4.94
ROE
126.9%
ROA
14.9%
Cash
$95.3M
Total Debt
$40.0M
Free CF
-$31.8M
52W Change
35.5%
Annual Financials
Cash vs Debt
Where RIGL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RIGL finished 44.46% above its 150-day moving average ($34.21) and 36.07% above its 200-day moving average ($36.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RIGL overbought or oversold?
At the September 3, 2026 close, RIGL's RSI(14) was 77.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $95.3M in cash and $40.0M in debt, RIGL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$31.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 126.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 14.9% further supports the picture of efficient asset utilization. Revenue has grown from $120.2M (2022) to $294.3M (2025), reflecting a 145% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing RIGL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.